On January 3, 2023 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, reported that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 AM PT at the Westin St. Francis Hotel in San Francisco, CA (Press release, Replimune, JAN 3, 2023, View Source [SID1234625750]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference.